Has Victoria Chang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,262 in general payments to Victoria Chang, MD across 55 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Victoria Chang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Victoria Chang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Victoria Chang, MD

Neurology · San Francisco, CANPI 1659833283

Payments from drug & device makers

$17,262in general payments, 2019–2025

Across 55 payments — averaging $313.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$13K
Medtronic$2K
Amneal Pharmaceuticals LLC$1K
Supernus Pharmaceuticals, Inc.$570
Teva Pharmaceuticals USA, Inc.$111
AbbVie$28
plus $20 from 1 others

What the payments were for

Consulting fees$7454%
Grants$12,50072%
Travel & lodging$1,3148%
Food & beverage$2,70416%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	7	$12,912
Medtronic	38	$2,459
Amneal Pharmaceuticals LLC	4	$1,161
Supernus Pharmaceuticals, Inc.	3	$570
Teva Pharmaceuticals USA, Inc.	1	$111
AbbVie	1	$28
Lilly USA, LLC	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,262 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$30,221

Medicare patients

110

Services billed

398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Carbidopa-LevodopaCarbidopa/Levodopa	66	$3,413
Carbidopa-Levodopa ErCarbidopa/Levodopa	24	$861
Propranolol Hcl	14	$295
Donepezil Hcl	24	$157
Mirtazapine	14	$118
Zonisamide	16	$106

Paid to pharmacies, not to this prescriber.

Other neurology in San Francisco

Bruce CreeSan Francisco$8M
Stanley PrusinerSan Francisco$6.5M
Adam BoxerSan Francisco$5.5M
Jennifer ClarkeSan Francisco$5.1M
Nancy Ann Oberheim BushSan Francisco$4.6M
Emmanuelle WaubantSan Francisco$3M
Jill OstremSan Francisco$2M
William JagustSan Francisco$2M
Gil RabinoviciSan Francisco$1.9M
Jonathan KatzSan Francisco$1.7M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →